ATAI Life Sciences (ATAI) Stock Surges Over 5% Amidst Biotech Industry Gains

Dec 20, 2024

Atai Life Sciences N.V. (ATAI, Financial) experienced a significant stock movement with a 5.04% rise, reaching $1.25 per share. The trading volume was 791,815 shares, with a turnover rate of 0.47% and a price fluctuation of 7.98%. Recent financial reports show revenue of $40,000, a net loss of $26.29 million, and an earnings per share of -$0.16. The gross profit stood at -$43,000, and the price-to-earnings ratio was -1.55. Currently, there are no institutional ratings for buying, holding, or selling the stock.

In the biotechnology sector, where ATAI operates, the overall growth was 0.88%. Notable performers include Abpro Holdings Inc and Aptose Biosciences, Inc., with significant activity and turnover rates. ATAI Life Sciences focuses on transforming mental health treatment with various clinical-stage biopharmaceutical products, including therapies involving psilocybin and MDMA derivatives. The company operates in the U.S. and Germany.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.